Hypothesis

Senescent CD8+ T cells release mitochondrial DNA that activates the cGAS‑STING pathway in stromal and epithelial cells, creating a paracrine senescence amplification loop that accelerates organismal aging independently of classic SASP cytokines.

Mechanistic Insight

Aged T cells accumulate defective mitochondria due to impaired mitophagy. When these organelles permeabilize, mitochondrial DNA escapes into the cytosol and is secreted via exosomes or extracellular vesicles. Extracellular mtDNA acts as a danger‑associated molecular pattern that binds cytosolic cGAS in neighboring non‑immune cells, triggering STING‑dependent IRF3 and NF‑κB activation. This signaling induces a transient interferon response followed by a sustained SASP‑like secretion of IL‑6, TNF‑α and IL‑1β, thereby converting nearby cells into a senescent state. The newly senescent stromal cells, in turn, secrete factors that further impair T‑cell mitochondrial function, closing a positive feedback loop. Unlike the SASP originating from senescent immune cells themselves, this mechanism places extracellular mtDNA as the primary initiator of tissue‑wide senescence propagation.

Novelty Beyond Cited Work

The synthesis highlights senescent immune cells as drivers of inflammaging and impaired surveillance. Here we add a specific organelle‑derived DAMP signal—mtDNA—that links T‑cell mitochondrial dysfunction directly to innate immune sensing in parenchymal cells. It's a mechanism that operates independently of the classic SASP. This reframes the immune system’s role: not only does it fail to clear senescent neighbors, it actively seeds senescence through a mitochondrial danger signal that bypasses cytokine‑only pathways.

Testable Predictions

• Restoring mitophagy in CD8+ T cells of aged mice will reduce circulating mtDNA levels and lower cGAS‑STING activation in lung, liver and kidney tissues.
• Genetic blockade of cGAS or STING specifically in stromal cells will attenuate senescence marker accumulation (p16^Ink4a, SA‑β‑gal) despite the presence of senescent T cells.
• We're going to measure plasma mtDNA by qPCR after administering a mtDNA scavenger (e.g., anti‑mtDNA antibody or DNase I); this will decrease systemic inflammaging biomarkers (serum IL‑6, CRP) and improve tissue regeneration after injury.
• Conversely, forcing mtDNA release from T cells (via TFAM heterozygous knockdown) in young mice will prematurely induce tissue senescence and shorten healthspan.

Experimental Design

1. Mouse models – Generate CD8‑Cre;Pink1^fl/fl (mitophagy‑deficient) and CD8‑Cre;Pink1^fl/fl;Pink1^OE (mitophagy‑overexpressing) lines. Include wild‑type controls.
2. Readouts – At 6, 12, 18 months measure:
   • Plasma mtDNA by qPCR.
   • Phospho‑STING and IRF3 levels in isolated lung fibroblasts and hepatocytes (Western blot, immunofluorescence).
   • Senescence burden (p16^Ink4a immunohistochemistry, SA‑β‑gal activity) in multiple organs.
   • Serum inflammaging cytokines (IL‑6, TNF‑α, IL‑1β) and clinical frailty index.
3. Interventions – Treat a cohort of aged wild‑type mice with intravenous DNase I (2 mg/kg twice weekly) for 8 weeks; parallel group receives IgG control.
4. Outcome analysis – Compare mtDNA burden, STING activation, senescence indices, and frailty between groups. Use two‑way ANOVA with genotype and treatment as factors; significance set at p<0.05.
5. Falsifiability – If mitophagy enhancement fails to lower plasma mtDNA or does not improve senescence/frailty metrics, the hypothesis is refuted. Likewise, if stromal‑specific cGAS/STING knockout does not reduce senescence despite high T‑cell mtDNA release, the proposed paracrine loop is not operative.

Potential Confounds and Controls

• Ensure that observed effects are not due to altered T‑cell numbers; normalize data to CD8+ counts.
• Verify that DNase I does not affect neutrophil NETosis independently; include a NETosis marker assay.
• Use littermate controls to mitigate background genetic variation.

This framework provides a concrete, falsifiable path to test whether mitochondrial DNA from senescent T cells acts as a master regulator of tissue‑wide senescence, offering a precise target for interventions that could uncouple immune aging from organismal decline.